Table 1 Incidence of clonal RAS pathway mutations among BCP-ALL patients with clinical risk factors

From: RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Risk parameter

Incidence of clonal mutations among

Statistics (clonal vs wild type)

 

Risk parameter: Yes

Risk parameter: No

Fisher’s

Odds ratio b

95% CI

   

Pa

  

Age ⩾10

22/75 (29%)

90/357 (25%)

0.88

  

Male

55/227 (24%)

57/205 (24%)

0.56

  

High WBC (>50/nl)

34/99 (34%)

78/331 (24%)

0.24

  

Down syndrome

2/16 (13%)

105/305 (27%)

0.10

0.3

0.03–1.38

CNS+

0/1 (0%)

24/248 (10%)

1

  

PPR

7/17 (41%)

51/181 (21%)

0.15

2.22

0.65–7.41

MRD high d33 ALL10

16/48 (33%)

35/147 (18%)

0.01

2.99

1.27–7.05

MRD high d79 ALL10

2/8 (25%)

47/171 (20%)

1

  
  1. Abbreviations: CNS+, non-traumatic puncture and >5 WBC/μl CSF with identifiable leukemic cells; patients with a traumatic lumbar puncture were not included; d33, at the end of induction therapy (day 33); d79, at the end of consolidation therapy (day 79); PPR, prednisone poor responder, that is, ⩾1000 leukemic blasts/μl in peripheral blood on day 8 of induction therapy; MRD high, minimal residual disease ⩾10−3; WBC, white blood cell count.
  2. aFisher’s exact test P-values <0.05 are printed in bold font.
  3. bOdds ratios are only given if P-values in Fisher’s exact test were <0.2.
Back to article page